指南与共识自身炎症与 IgG4 相关病

EULAR/PReS 认可的家族性地中海热(FMF)管理推荐:2024 年更新

EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update.
指南 / 共识 · Ann Rheum Dis · 2025-04-09

该 2024 年更新由多学科小组基于系统评价和德尔菲调查制定,包含 4 条总体原则和 12 条推荐,每条附有 0-10 分的同意度、证据等级和依据,所有条目同意度均大于 9/10,多数更新条目的证据等级有所提高,并强调提高依从性。

要点

  • 最终推荐集包括 4 条总体原则和 12 条推荐,每条均附同意度、证据等级和依据。
  • 所有条目的同意度均大于 9/10,多数更新条目的证据等级有所提高。
  • 多个条目强调提高依从性是重要方面,并包含优先集、质量指标和实施策略。

核心结论

  • 该文章提出一套被广泛接受的家族性地中海热治疗和监测推荐,基于最佳可用证据和专家意见,有助于指导医生照护家族性地中海热患者。

研究设计与样本

  • 组建了来自东地中海地区和欧洲的多学科小组,包括风湿科医生、内科医生、儿科医生、肾科医生、职业治疗师、物理治疗师、2 名方法学家和 2 名患者代表。
  • 对家族性地中海热的药物治疗及其并发症进行了多项系统评价,结合更新证据修订既往推荐并纳入新的证据等级,通过德尔菲调查获得对推荐的同意度。

主要发现

  • 最终推荐集包含 4 条总体原则和 12 条推荐,每条呈现同意度(0-10)、证据等级和依据。
  • 所有条目的同意度均大于 9/10,多数更新条目的证据等级有所提高。
  • 多个条目强调提高依从性是重要方面,新推荐包括优先集、质量指标和其他建议的实施策略。

关键数值与推荐

  • 每条推荐的同意度以 0-10 分表示,所有条目同意度均大于 9/10。
  • 每条推荐均附有证据等级和依据,多数更新条目的证据等级较前提高。

临床怎么用

  • 这些推荐旨在指导风湿科医生和其他卫生专业人员在家族性地中海热患者的治疗和随访中进行临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease despite being a rare disease for many rheumatologists. These evidence-based recommendations update the ones issued in 2016 to account for the recent developments in the field and aim to guide rheumatologists and other health professionals in the treatment and follow-up of patients with FMF. METHODS: A multidisciplinary panel was assembled, including rheumatologists, internists, paediatricians, a nephrologist, an occupational therapist, a physiotherapist, 2 methodologists, and 2 patient representatives, all from the Eastern Mediterranean area and Europe. Several systematic reviews were performed on the pharmacological treatment of FMF and its complications. The previous recommendations were revised considering the updated evidence, and the new levels of evidence were incorporated. The agreement with the recommendations was obtained through a Delphi survey. RESULTS: The final set comprises 4 overarching principles and 12 recommendations, each presented with its degree of agreement (0-10), level of evidence, and rationale. The degree of agreement was greater than 9/10 in all instances, and the level of evidence improved in most updated statements. Improving adherence is emphasised as an important aspect in several statements. These new recommendations include a priority set, quality indicators, and other suggested implementation strategies. CONCLUSIONS: This article presents a set of widely accepted recommendations for treating and monitoring FMF, supported by the best available evidence and expert opinion. These recommendations are valuable for guiding physicians in caring for patients with FMF.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ozen S, Sağ E, Oton T, et al. EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update. Ann Rheum Dis. 2025. PMID: 40234174. doi:10.1016/j.ard.2025.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。